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A
 
BSTRACT
Background:
 
Adenosine monophosphate (AMP) acts
by releasing inflammatory mediators from mast cells
and may be used for bronchial and nasal provocation
tests. The aim of the present study was to determine
whether AMP could be used in a dose–response
manner to evaluate nasal function and to evaluate the
reproducibility of nasal function measurements with
nasal challenge testing using histamine and AMP in
patients with perennial allergic rhinitis.
 
Methods:
 
Nine patients were challenged on three
separate occasions for each challenge with doubling
doses of either histamine (0.25–8 mg/mL) or AMP
(25–800 mg/mL). Challenge measurements were made
of peak inspiratory flow rate (PIFR), acoustic rhino-
metry (AR) and rhinomanometry (Rhino). The provoca-
tion concentration (PC
 
30
 
) was calculated in order to
produce: (i) a 30% fall in PIFR; (ii) a 30% fall in AR and
(iii) a 30% increase in nasal airway resistance in
Rhino and a symptom score of 10 (of 40). The mean
intrasubject coefficient of variation (CV) was calculated
for baseline and the corresponding PC.
 
Results:
 
Baseline CV prior to histamine were 15.1,
19.6 and 15.8 for PIFR, AR and Rhino, respectively;
prior to AMP, baseline CV were 12.7, 19.6 and 10.6%
for PIFR, AR and Rhino, respectively. For histamine
challenge, the PC
 
30
 
 were 26.5, 27.4 and 38.7% for
PIFR, AR and Rhino, respectively. For AMP challenge,
the PC
 
30
 
 CV values were 46.2, 30.8 and 49.5% for
PIFR, AR and Rhino, respectively. There was no sig-
nificant difference in the provocative dose required
to cause a predetermined change in response or the
response at 1 mg/mL histamine and 100 mg/mL
AMP.
 
Conclusions:
 
Adenosine monophosphate may be
used as a challenge agent for nasal challenge testing,
although it results in greater variability than histamine.
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I
 
NTRODUCTION
 
One component of mucosal inflammation is that of
hyperresponsiveness, a reaction to contact of substances
at lower concentrations than would normally be the
case. The substance used for the nasal provocation tests
can be considered as ‘specific’, such as allergens
 
1
 
 or
aspirin,
 
2,3
 
 or ‘non-specific’, such as histamine.
 
4
 
 Hista-
mine is an example of a direct challenge test because it
acts directly on histamine receptors in the nasal mucosa.
It is less representative of the clinical situation than
indirect challenges with, for example, allergen. Allergen
challenges are popular in diagnosing specific allergy
and have been shown to be more sensitive to skin prick
testing.
 
5,6
 
 However, these challenges assess a specific
allergen and cannot be used for assessing the effect of
therapy on a mixed population with allergies to different
allergens. Recently, Polosa 
 
et al
 
.
 
7
 
 have published data
showing that challenging the nasal mucosa with adeno-
sine monophosphate (AMP), an indirect stimulus, results
in histamine release from primed mast cells in atopic
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subjects. Adenosine monophosphate bronchial chal-
lenge has been confirmed to be a useful method of
assessing asthma
 
8
 
 and it is possible that AMP nasal
challenge may have a role in assessing upper airway
disease. However, prior to proceeding with studies
assessing the ability of AMP nasal challenge in determin-
ing nasal inflammation and response to treatment, it is
necessary to determine whether a dose–response effect
with AMP exists and which doses should be used.
With nasal challenge testing, responses to stimuli are
normally assessed by measuring nasal blockage, nasal
discharge and sneezing.
 
9
 
 Although the response can be
calculated by weighing handkerchiefs and counting the
number of sneezes, it is the obstructive component that
is most easily and reproducibly measured.
 
1,10
 
 This can
be measured by rhinomanometry, acoustic rhinometry
(AR) and nasal flow, although there is debate as to
the  optimal measure. Rhinomanometry is commonly
used,
 
11–13
 
 although some authors prefer AR.
 
14
 
 Acoustic
rhinometry has been compared with rhinomanometry by
body plethsymography,
 
15
 
 anterior rhinometry
 
16
 
 and pos-
terior rhinomanometry
 
17
 
 during nasal challenge tests. In
all these studies, rhinomanometry was as sensitive as AR;
however, Roithmann 
 
et al
 
.
 
15
 
 and Austin and Foreman
 
17
 
have suggested that AR is easier to perform. Peak inspir-
atory flow rate (PIFR) can also be used to assess the
response to stimulus in terms of challenge testing
 
10
 
 and
has been shown to be as sensitive as AR.
 
18
 
 In the present
study, we wished to evaluate the coefficient of variation
(CV) by using PIFR, AR, rhinomanometry and symptoms
at the same time. We chose to use posterior rhino-
manometry because it assesses the total nasal resistance
 
M
 
ETHODS
 
Patients
 
Nine patients (four females) with perennial allergic
rhinitis, according to current criteria,
 
19
 
 mean (
 
±
 
 SEM)
age 34.4 
 
±
 
 4.2 years, were recruited into the study and
underwent a histamine nasal challenge test and AMP
challenge test. All patients had normal spirometry (mean
forced expiratory volume in 1 s (FEV
 
1
 
) 101 
 
±
 
 2.8%
predicted), seven patients were skin prick positive to
grass, five were skin prick positive to house dust mite,
five were skin prick positive to cat and four were skin
prick positive to dog. Three patients were unable to
perform the rhinomanometry due to technical reasons.
There was a subgroup of six patients (two female), mean
(
 
±
 
 SEM) age 31.0 
 
±
 
 3.6 years, FEV
 
1
 
 105 
 
±
 
 2.4%
predicted, allergic to grass (
 
n
 
 = 4), house dust mite
(
 
n
 
 = 3), cat (
 
n
 
 = 4) and dog (
 
n
 
 = 3) who performed all
measurements; one additional person did not have
evaluable results for AMP. Patients who were skin prick
positive to a seasonal allergen performed the study out
with the season for their allergen. One patient was
taking oral loratadine prior to enrolment into the study,
but no patient was taking intranasal corticosteroids. No
subject had received oral corticosteroids or antibiotics
for 6 months prior to the study. All subjects were non-
smokers and had normal full blood count, biochemical
profile and urinalysis. Approval for the study was
obtained from the Tayside Medical Ethics Committee
and all patients gave their written informed consent to
participate.
 
Methodology
 
Patients attended the laboratory for each challenge on
three separate occasions. Each occasion was separated
by more than 3 days. No patient had received any
medication for their perennial allergic rhinitis for at least
1 week prior to each study visit. All measurements at the
study visit were conducted at the same time of day for
each patient.
 
Measurements
 
Adenosine monophosphate nasal challenge
 
Patients had baseline measurements of nasal PIFR, AR,
symptoms scoring and rhinomanometry. The above
measurements were repeated 2 min after receiving a
placebo nasal spray. Adenosine monophosphate was
then administered via a nasal spray in doubling concen-
trations from 25 to 400 mg/mL, with the measurements
repeated 2 min after each dose. The study was termi-
nated on the request of the patient if the symptoms were
severe or by the physician if the patient had an
unrecordable PIFR or AR value. Patients were then
offered topical xylometazoline (Otrivine; Norvartis Con-
sumer Health, West Sussex, UK) and observed until their
symptoms of nasal blockage subsided.
 
Nasal histamine challenge
 
Nasal histamine challenge was performed in the same
manner as the AMP challenge. After a placebo baseline,
patients were given doubling concentrations of histamine
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from 0.25 to 8 mg/mL. The following measurements
were performed 2 min after each concentration.
 
Nasal PIFR
 
Nasal inspiratory flow rate was measured
using an In-check™ flow meter (Clement Clarke Inter-
national, Harlow, UK). After blowing their nose, patients
inspired forcefully from residual volume to total lung
capacity with their mouth closed. All measurements were
made while in the sitting position with a good seal
around a purpose-built facemask. The mean of three
consecutive readings was recorded.
 
Rhinomanometry
 
Patients had measurements of nasal
resistance by posterior rhinomanometry using an NR6
rhinomanometer (GM Instruments, Ashgrove, Kilwin-
ning, UK) with on-line computerized integration of total
nasal flow and pressure change in a subgroup of six
patients with histamine and five patients with AMP nasal
challenge. Total nasal flow was measured with patients
breathing tidal volumes through a facemask with their
mouths closed. Nasal pressure was measured by placing
a pressure probe in the patients’ mouth with their
soft palate open to represent posterior nasal pressure
changes. Flow rates were calculated at a nasal pressure
of 150 Pa.
 
20
 
 The pressure transducer and flow meter
were calibrated weekly.
 
Acoustic rhinometry
 
Acoustic rhinometry was meas-
ured using a AI Executive acoustic rhinometer (GM
Instruments). A probe was inserted 0.5 cm into each
nostril such that a seal was obtained without distorting
the nasal architecture. Patients were asked to hold their
breath during the procedure and a probe stand was
used in order to ensure correct positioning of the
probe.
 
21
 
 Measurements were of the minimum cross-
sectional area (MCA) at the nasal valve (approximately
2 cm from nasal orifice). The total minimum area was
taken to be sum of the measurement from the right and
left nostrils.
 
Symptoms
 
Patients were asked to score their symptoms on an
11-point scale (0, no symptoms; 10, severe symptoms)
in terms of ‘runny nose’, ‘blocked/stuffy nose’, ‘itchy
nose’ and ‘overall discomfort/feeling’. The total
symptom score (out of 40) was the sum of the individual
components.
 
Statistical analysis
 
Log dose–response curves were produced for each
measurement. Provocation concentrations producing a
30% (PC
 
30
 
) fall for nasal inspiratory flow rate and MCA
and a 30% increase in nasal airways resistance were
determined by interpolation of the curve. For total
symptom score, the concentration required to cause a
score of 10 was calculated from the log dose–symptom
curve.
The intrasubject CV for repeated measures was cal-
culated for AMP and histamine for each end-point. For
AMP nasal challenge testing, the CV for rhinomanometry
could only be calculated in three patients. Coefficients of
variation were also calculated for baseline values and for
the response after 1 mg/mL histamine and 100 mg/mL
AMP.
Student’s 
 
t
 
-test was used to determine any significant
difference between the baseline values and the value at
1 mg/mL histamine or 100 mg/mL AMP. Overall com-
parisons of the actual value of PC
 
30
 
 and CV for outcome
measure after both AMP and histamine challenge were
made by multifactorial analysis of variance using subject
and outcome measure (PIFR, symptoms, AR) as factors.
This was followed by Bonferroni’s multiple range testing
(set at 95% confidence interval (CI)) in order to obviate
multiple pair-wise comparisons. Consequently, compari-
sons are only denoted as being significant (
 
P
 
 < 0.05,
two-tailed) or not significant. This analysis could not be
performed for AMP challenge in the subgroup who per-
formed rhinomanometry due to the small number of
patients in this subgroup. The analysis was performed
using Statgraphics statistical software package (STSC
Software Publishing Group, Rockville, MD, USA) and
Microsoft Excel 97 (Microsoft, Seattle, WA, USA).
 
R
 
ESULTS
 
It was possible to generate dose–response curves for
both AMP and histamine using PIFR, AR, rhinomano-
metry and symptom scoring. The average dose–
response curves for PIFR and AR are illustrated in Fig. 1
with a value of zero being assigned where recordings of
PIFR and AR were below the detectable limit of the test.
It was not possible to generate a CV for provocation
with AMP in three patients with AR, two patients with
rhinomanometry and PIFR and symptoms and in one
patient for symptoms with histamine. Overall compari-
sons of the actual value of PC
 
30
 
 and CV for outcome
measure after both AMP and histamine challenge were
not performed for rhinomanometry due to the small
number of patients.
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The response at baseline (i.e. prior to challenge) and
at 1 mg/mL histamine and 100 mg/mL AMP are given in
Table 1. There was no significant difference in baseline
values or values after 1 mg/mL histamine and 100 mg/
mL AMP for any measure. The provocation concentra-
tions with both challenges for each outcome measure-
ment are also shown in Table 1. For histamine challenge
testing, there was a 0.1 (95% CI –1.6, 1.8) doubling
dose difference for PIFR compared with symptoms and a
0.6 (95% CI –1.1, 2.3) dose difference for PIFR com-
pared with AR. For AMP challenge, there was a 0.9 (95%
CI –0.7, 2.5) doubling dose difference between PIF and
symptoms and a 0.4 (95% CI –1.4, 2.1) doubling dose
difference between PIFR and AR. There was no significant
difference between the provocation concentration with
AMP or histamine for any measure (Table 1).
The CV at baseline, after 1 mg/mL histamine and
100 mg/mL AMP and for the doubling dose difference is
shown in Table 2. Although the CV for measurements
tended to be greater with AMP challenge than with hista-
mine challenge, especially for symptoms and PIFR, this
was not statistically significant. For histamine challenge,
 
Fig. 1
 
(a) Average dose–response curves for minimal cross-sectional area as assessed by acoustic rhinometry for 0.25 and
25 mg/mL (0.25/25), 0.5 and 50 mg/mL (0.5/50), 1 and 100 mg/mL (1/100), 2 and 200 mg/mL (2/200), 4 and 400 mg/mL
(4/400) and 8 and 800 mg/L (8/800) for histamine (
 

 
) and adenosine monophosphate (
 

 
), respectively. (b) Average
dose–response curves for peak inspiratory flow rate.
 
Table 1
 
Baseline values prior to histamine and AMP nasal challenge, values after 1 mg/mL histamine and 100 mg/mL AMP and
the provocative concentration of histamine and AMP causing a 30% fall in nasal peak inspiratory rate, a total symptom score of 10,
a 30% fall in acoustic rhinometry minimal cross-sectional area and a 30% increase in airway resistance as measured by
rhinomanometry
PIFR Symptom score Acoustic rhinometry Rhinomanometry
Histamine
Baseline 147 
 
± 
 
15 L/min 2.7 
 
± 
 
1.5 units 1.1 
 
± 
 
0.1 cm
 
2
 
198 
 
± 
 
10 Pa/cm
 
3
 
 per s
1 mg/mL 105 
 
± 
 
13 L/min 10.6 
 
± 
 
1.6 units 0.7 
 
± 
 
0.1 cm
 
2
 
515 
 
± 
 
103 Pa/cm
 
3
 
 per s
Provocative concentration 1.03 
 
± 
 
0.18 mg/mL 0.71 
 
± 
 
0.55 mg/mL 0.67 
 
± 
 
0.15 mg/mL 0.55 
 
± 
 
0.16 mg/mL
AMP
Baseline 153 
 
± 
 
13 L/min 3.0 
 
± 
 
1.4 units 1.0 
 
± 
 
0.1 cm
 
2
 
180 
 
± 
 
15 Pa/cm
 
3
 
 per s
100 mg/mL 129 
 
± 
 
16 L/min 9.9 
 
± 
 
1.4 units 0.8 
 
± 
 
0.1 cm
 
2
 
356 
 
± 
 
69 Pa/cm
 
3
 
 per s
Provocative concentration 180 
 
± 
 
66 mg/mL 97 
 
± 
 
22 mg/mL 125 
 
± 
 
34 mg/mL 69 
 
± 
 
22 mg/mL
 
P
 
 value* 0.11 0.80 0.13 0.69
 
Data show the mean 
 
± 
 
SEM.
*The 
 
P
 
 values given are for the provocative concentration of AMP compared with histamine.
PIFR, peak inspiratory flow rate; AR, acoustic rhinometry minimal cross-sectional area.
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there was a 2.1% (95% CI –19, 23%) difference between
PIFR and symptoms and a 0.9% (95% CI –19, 21%)
difference between PIFR and AR. For AMP challenge,
there was a 4.2% (95% CI –29, 36%) difference between
PIFR and symptoms and a 15.3% (95% CI –25, 55%)
difference between PIFR and AR.
 
D
 
ISCUSSION
 
We have shown that it is possible to use AMP as the
stimulus in a dose-ranging manner and to detect a
dose–response effect by measuring PIFR, MCA using AR,
airways resistance using rhinomanometry and symptom
scoring. The provocation concentration for measure-
ments with AMP was in the same order of magnitude to
histamine when compared on a 100 : 1 basis and there
was no difference in response after 100 mg/mL AMP
and 1 mg/mL histamine. This suggests that the doses of
AMP chosen were appropriate, although the present
study was not designed to compare the response of AMP
and histamine.
However, it was not possible to generate a PC
 
30
 
 or a
CV for the nasal challenge in all patients with all end-
points with both challenges. Furthermore, the CV for
measurements with the AMP challenge tended to be
greater than with the histamine challenge. However, if a
non-specific indirect nasal challenge test is required for
evaluation or research, then AMP nasal challenge may
be suitable.
The CV was similar for all chosen end-points (i.e. AR,
PIFR, rhinomanometry and symptoms). For this reason, it
may be possible to use PIFR as a simple alternative to the
more expensive laboratory measures of nasal function.
This would mean that nasal challenge testing could be
performed, on a screening basis, in the laboratory; how-
ever, larger studies would be required to validate this
further. In this respect, we have shown recently that by
using nasal PIFR, but not AR or rhinomanometry, as the
end-point of nasal challenge testing with histamine, it was
possible to detect a significant difference with treatment
with intranasal mometasone.
 
22
 
Pirila 
 
et al
 
.
 
16
 
 compared AR and rhinomanometry using
allergen challenge and showed that the CV was lower
with AR than rhinomanometry. However, in that study,
anterior rather than posterior rhinomanometry was
performed. Gleeson et al.23 also compared PIFR, AR and
rhinomanometry after low- (0.4%) and high-dose (0.8%)
histamine and showed that there was comparable sensi-
tivity and significant correlation between all methods.
With bronchial challenge testing, the standard cut-off
used for a change in response is a 20% fall for FEV1;
however, there is no such standard value for the different
measures of nasal function in nasal challenge testing.
Pirila et al.16 used a 15% decrease in MCA and a 50%
increase in nasal resistance after 30 min, and 30 and
100% changes, respectively, after 60 min. Alternatively,
with airway resistance, Gianico et al.12 used 100%
change and Kanthawatana et al.13 suggested a 300%
increase. When assessing measures of nasal flow, Plavec
et al.10 used a value of a 30% fall because this had been
shown to be significant in a pilot study. We also used
a 30% decrease in nasal peak inspiratory flow and
showed that the concentration required was similar to
that causing significant symptoms (total symptoms score
of 10).
Our study was limited by the small sample size,
although the study was designed as a proof of concept
study and not to compare the effect of AMP and
Table 2 Mean intrasubject coefficient of variation for repeated measures at baseline prior to histamine and AMP nasal challenge
and after 1 mg/mL histamine and 100 mg/mL AMP and for the provocative concentration of histamine and AMP causing a 30%
fall in nasal peak inspiratory rate, a total symptom score of 10 and a 30% reduction in acoustic rhinometry minimal cross-sectional
area and a 30% increase in airway resistance as measured by rhinomanometry
PIFR Symptom score AR Rhinomanometry
Histamine
Baseline 15.1 19.6 15.8
1 mg/mL 23.1 22.9 24.8 32.6
Provocative concentration 26.5 24.4 27.4 38.7
AMP
Baseline 12.7 19.6 10.6
100 mg/mL 21.7 37.8 20.3 39.0
Provocative concentration 46.2 41.9 30.8 49.5
PIFR, peak inspiratory flow rate; AR, acoustic rhinometry minimal cross-sectional area.
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histamine nasal challenge. The statistical analysis is for
illustrative information only and the non-significant differ-
ence between AMP and histamine does not suggest that
these challenges are equivalent. Furthermore, we did not
assess healthy non-atopic volunteers, so that we cannot
comment on sensitivity or specificity of the AMP nasal
challenge test. However, because we have demonstrated
that it is possible to use AMP as a stimulus for nasal
challenge in a log dose–response manner, it is now
possible to evaluate any theoretical benefits that nasal
AMP challenge may have on assessing the degree of
nasal inflammation and response to treatment with rhini-
tis therapy.
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